GLS-012

· Guangzhou Gloria Biosciences Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GLS-012, covering 2023-08-07 to 2023-08-07. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

See pricing